Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

Exclusion Criteria

• •Genotype 2, 3, 5 or 6 infection.
• •Decompensated cirrhosis defined by the presence of actual or previous history of clinical decompensation including ascites, hepatic encephalopathy, variceal bleeding or spontaneous bacterial peritonitis, or a Child-Pugh B or C.
• •Hepatocellular carcinoma after liver transplantation.
• •Total bilirubin \> 3 mg/dL.
• •Immunosuppression with cyclosporine or an mTOR inhibitor (everolimus or sirolimus).
• •Severe extrahepatic diseases: cardiovascular, respiratory, cerebrovascular and poorly controlled diabetes.
• •Platelets \< 75 x 109 cells/L.
• •Neutrophil count \< 0.5 x 109 cells/L.
• •Hemoglobin \< 9 g/dL.
• •Albumin \< 3g/dL.
• •HIV infection.
• •Hepatitis B infection.
• •Active intake of toxic amounts of alcohol or recreational drugs.
• •Females who are pregnant, become to be pregnant or breastfeeding or males whose partners are pregnant, become to be pregnant or breastfeeding.
• •Intake of disallowed medications including(but not limited to):
• •1. Antibiotics: clarithromycin, erythromycin, telithromycin, nafcillin, rifampin
• •2. Antifungals: itraconazole, ketoconazole, voriconazole
• •3. Antihypertensives: nifedipine
• •4. Anticonvulsants: carbamazepine, phenytoin, phenobarbital
• •5. Bosentan
• •6. Modafinil
• •7. St.Jonh's Wort
• •8. Immunosuppressants: cyclosporin, everolimus, sirolimus
• •9. Diabetes agents: glibenclamide, glyburide
• •10. Lipid lowering agents: gemfibrozil
• •11. Eltrombopag
• •12. Lapatinib
• •13. HIV medications: efavirenz, etravirine, all ritonavir boosted and unboosted HIV protease inhibitors
• •14. Statins: simvastatin, fluvastatin, rosuvastatin at doses greater than 10 mg/d, atorvastatin at doses greater than 10 mg/d.